FDA Inspection 1180553 — AvKARE
The FDA completed an inspection of AvKARE on August 23, 2022 in Pulaski, TN. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- August 23, 2022
- Fiscal Year
- 2022
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Pulaski, TN (United States)
Additional Details
Postmarket Adverse Drug Experience (PADE)